TY - JOUR T1 - <em>G6PD</em> variant distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19 JF - medRxiv DO - 10.1101/2020.05.27.20114066 SP - 2020.05.27.20114066 AU - Jorge da Rocha AU - Houcemeddine Othman AU - Caroline T. Tiemessen AU - Gerrit Botha AU - Michèle Ramsay AU - Collen Masimirembwa AU - Clement Adebamowo AU - Ananyo Choudhury AU - Jean-Tristan Brandenburg AU - Mogomotsi Matshaba AU - Gustave Simo AU - Francisco-Javier Gamo AU - Scott Hazelhurst AU - as members of the H3Africa Consortium Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/02/2020.05.27.20114066.abstract N2 - Chloroquine/hydroxychloroquine have been proposed as potential treatments for COVID-19. These drugs have warning labels for use in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Analysis of whole-genome sequence data of 458 individuals from sub-Saharan Africa showed significant G6PD variation across the continent. We identified nine variants, of which four are potentially deleterious to G6PD function, and one (rs1050828) that is known to cause G6PD deficiency. We supplemented data for the rs1050828 variant with genotype array data from over 11,000 Africans. Although this variant is common in Africans overall, large allele frequency differences exist between sub-populations. African sub-populations in the same country can show significant differences in allele frequency (e.g. 16.0% in Tsonga vs 0.8% in Xhosa, both in South Africa, p = 2.4 × 10−3). The high prevalence of variants in the G6PD gene found in this analysis suggests that it may be a significant interaction factor in clinical trials of chloroquine and hydrochloroquine for treatment of COVID-19 in Africans.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe AWI-Gen Collaborative Centre is funded by the NIH/NHGRI (Grant U54HG006938) as part of the H3Africa Consortium. MR is a South African Research Chair in Genomics and Bioinformatics of African Populations hosted by the University of the Witwatersrand, funded by the Department of Science and Technology, and administered by National Research Foundation of South Africa (NRF). The TrypanoGEN project was funded by the Wellcome Trust, study number 099310/Z/12/Z. The Collaborative African Genetics Network (CAfGEN) is funded by the NIH/NHGRI (grant CAfGEN 1U54AI110398). The whole genome sequencing of the H3A Data was supported by a grant from the National Human Genome Research Institute, National Institutes of Health (NIH/NHGRI) U54HG003273. Cell Biology Research Lab component: This work is based on the research supported by grants awards from the Strategic Health Innovation Partnerships (SHIP) Unit of the South African Medical Research Council, a grantee of the Bill \&amp; Melinda Gates Foundation, and the South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation of South Africa (84177). JdR was partially funded by the SA National Research Foundation (SFH170626244782). GSK had no part in the design of this study or analysis presented here and the views and opinions expressed are not necessarily those of GSK. The authors acknowledge the financial support of GSK.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Research Ethics Committee (Medical), University of the Witwatersrand; Clearance Certificate NO. M190541All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatasets used in this study were generated as part of the Human Heredity and Health in Africa Project (H3Africa). H3Africa is committed submit these datasets to the European Genome-Phenome Archive (EGA), where access can be obtained through the H3Africa Data and Biospecimen Access Committee. https://ega-archive.org/search-results.php?query=h3africa ER -